NYSE · LLY
Eli Lilly and Company
$1,373.00+$84.70 (+6.57%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.51% below the high.
Loading market information…
NASDAQ · PRCT · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
PROCEPT BioRobotics Corporation’s quoted price sits in the lower half of its reported 52-week range, 46.73% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
PROCEPT BioRobotics Corporation’s next earnings report is currently expected on Nov 4, 2026, with estimated earnings per share of -$0.39. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow PROCEPT BioRobotics Corporation’s reporting calendar.
THE COMPANY BEHIND THE TICKER
PROCEPT BioRobotics Corporation specializes in pioneering surgical robotic technologies, offering innovative solutions within the field of urology. Its flagship product is the AquaBeam Robotic System, a sophisticated, image-guided surgical robot designed for minimally invasive urological procedures. This system primarily facilitates Aquablation therapy, which the company also devised, to alleviate lower urinary tract symptoms in male patients diagnosed with benign prostatic hyperplasia (BPH). As of year-end 2021, PROCEPT BioRobotics had successfully deployed 130 AquaBeam Robotic Systems across the globe, with a significant majority—78 units—located in the United States. Founded in 2007, the corporation maintains its headquarters in Redwood City, California.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:12 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | Apr 24, 2025 | -$0.45+8.16% vs estimate | $69.16M+5.69% vs estimate |
|---|
| Q4 2024 | Feb 25, 2025 | -$0.35-2.94% vs estimate | $68.24M-10.19% vs estimate |
|---|
| Q3 2024 | Oct 28, 2024 | -$0.40+16.67% vs estimate | $58.37M-12.58% vs estimate |
|---|
THE ANALYST VIEW
16 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 9 contributors · Median target $21.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$1,373.00+$84.70 (+6.57%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.51% below the high.
$275.20+$4.16 (+1.53%)
Johnson & Johnson’s quoted price sits in the upper half of its reported 52-week range, 2.09% below the high.
$290.97+$4.98 (+1.74%)
AbbVie Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.55% below the high.
$146.33+$5.40 (+3.83%)
Merck & Co., Inc.’s quoted price sits in the upper half of its reported 52-week range, 6.75% below the high.
$2.38-$0.06 (-2.46%)
SS Innovations International, Inc.’s quoted price sits in the lower half of its reported 52-week range, 73.05% below the high.
$10.69+$0.13 (+1.23%)
ClearPoint Neuro, Inc.’s quoted price sits in the lower half of its reported 52-week range, 57.21% below the high.
$4.17-$0.09 (-2.11%)
EDAP TMS S.A. American Depositary Shares’s quoted price sits in the upper half of its reported 52-week range, 34.84% below the high.
$1.12$0.00 (0.0%)
Microbot Medical Inc.’s quoted price sits in the lower half of its reported 52-week range, 60.84% below the high.
